Log In
BCIQ
Print this Print this
 

ASM8 (formerly TPI ASM8)

Also known as: formerly TPI-ASM8

  Manage Alerts
Collapse Summary General Information
Company Pharmaxis Ltd.
DescriptionDual modified phosphorothioate antisense oligonucleotides that down-regulate the expression of CC chemokine receptor 3 (CCR3) and the common beta chains for the receptors for IL-3, IL-5 and GM-CSF
Molecular Target CC chemokine receptor 3 (CCR3) (CD193) ; Cytokine receptor common beta chain
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase II
Standard IndicationAsthma
Indication DetailsTreat allergen-induced asthma; Treat asthma; Treat mild to moderate asthma; Treat moderate to severe asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$20.6M

0

$12.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/15/2010

$20.6M

0

$12.6M

Get a free BioCentury trial today